Edition:
India

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

18.88USD
16 Aug 2019
Change (% chg)

$0.37 (+2.00%)
Prev Close
$18.51
Open
$18.73
Day's High
$19.24
Day's Low
$18.47
Volume
244,961
Avg. Vol
307,908
52-wk High
$23.43
52-wk Low
$8.34

Latest Key Developments (Source: Significant Developments)

Coherus Biosciences Posts Q2 EPS Of $0.32
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.32.Q2 EARNINGS PER SHARE ESTIMATE $-0.00 -- REFINITIV IBES DATA.NET PRODUCT REVENUE FOR Q2 OF 2019 WAS $83.4 MILLION.CASH, CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES FOR Q2 TOTALED $111.9 MILLION AT JUNE 30, 2019.  Full Article

Coherus BioSciences Says Reports Victory in Pegfilgrastim Patent Dispute
Tuesday, 30 Jul 2019 

July 29 (Reuters) - Coherus Biosciences Inc ::US COURT OF APPEALS FOR FEDERAL CIRCUIT AFFIRMS DECISION OF A US DISTRICT COURT THAT CO'S UDENYCA DOES NOT INFRINGE AMGEN'S ASSERTED PATENT.FEDERAL CIRCUIT'S PRECEDENTIAL OPINION AFFIRMED DISTRICT COURT'S JUDGMENT IN COHERUS' FAVOR.  Full Article

Coherus Biosciences Files Patent Infringement Suit Against Amgen
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES ANNOUNCES FILING OF PATENT INFRINGEMENT SUIT AGAINST AMGEN DIRECTED TO AMGEN’S HUMIRA BIOSIMILAR FORMULATION.COHERUS BIOSCIENCES - EACH OF ASSERTED COHERUS PATENTS IS DIRECTED TO STABLE FORMULATIONS OF ADALIMUMAB.COHERUS BIOSCIENCES - CONTINUES TO EVALUATE OPTIONS AND POTENTIAL STRATEGIES FOR EX-U.S. COMMERCIALIZATION OF CHS-1420.  Full Article

Coherus Biosciences Secures $75 Mln Credit Financing With Healthcare Royalty Partners
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES SECURES $75 MILLION CREDIT FINANCING WITH HEALTHCARE ROYALTY PARTNERS.COHERUS BIOSCIENCES INC - SENIOR SECURED CREDIT FACILITY MATURES ON JANUARY 7, 2025.  Full Article

Coherus Biosciences Receives European Commission Approval For Udenyca (Pegfilgrastim Biosimilar)
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES RECEIVES EUROPEAN COMMISSION APPROVAL FOR UDENYCA™ (PEGFILGRASTIM BIOSIMILAR).COHERUS BIOSCIENCES INC - UDENYCA™ IS CURRENTLY UNDER EVALUATION BY U.S. FEDERAL DRUG ADMINISTRATION (FDA) WITH AN ACTION DATE OF NOVEMBER 3, 2018.  Full Article

Coherus Biosciences Q2 Loss Per Share $0.68
Thursday, 9 Aug 2018 

Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.68.Q2 EARNINGS PER SHARE VIEW $-0.64 -- THOMSON REUTERS I/B/E/S.SEES CASH USE IN OPERATIONS OF ABOUT $48 TO $53 MILLION FOR Q3.COHERUS BIOSCIENCES - CASH AND CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES TOTALED $159.8 MILLION AT QUARTER-END VERSUS $95.2 MILLION AS OF MARCH 31.  Full Article

Coherus Biosciences Receives Positive CHMP Opinion For UDENYCA™ (Pegfilgrastim Biosimilar Candidate)
Friday, 27 Jul 2018 

July 27 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES RECEIVES POSITIVE CHMP OPINION FOR UDENYCA™ (PEGFILGRASTIM BIOSIMILAR CANDIDATE).COHERUS BIOSCIENCES - EUROPEAN COMMISSION DECISION ON APPROVAL FOR UDENYCA IS EXPECTED IN OCTOBER.  Full Article

Coherus Says Subsequent To CHMP Meet Of June 27 To Consider Chs-1701 Application
Wednesday, 18 Jul 2018 

July 17 (Reuters) - Coherus BioSciences Inc ::COHERUS- SUBSEQUENT TO CHMP MEET OF JUNE 27 TO CONSIDER CHS-1701 APPLICATION, CHMP IDENTIFIED SOME OUTSTANDING ISSUES ARISING FROM DAY 180 RESPONSES.COHERUS BIOSCIENCES SAYS SUBMITTED A FULL RESPONSE TO CHMP ISSUES ON JULY 3 2018 - SEC FILING.COHERUS BIOSCIENCES-NOW GOT WRITTEN (CO)-RAPPORTEURS JOINT ASSESSMENT REPORT STATING CONCLUSION THAT OUTSTANDING ISSUES WERE SATISFACTORILY ADDRESSED.COHERUS BIOSCIENCES INC - EXPECTS CHS-1701 APPLICATION WILL BE INCLUDED ON AGENDA FOR JULY 2018 CHMP MEETING.COHERUS BIOSCIENCES INC - UNDERSTANDS THAT JOINT ASSESSMENT REPORT IS NOW UNDER REVIEW BY CHMP.COHERUS BIOSCIENCES - NOW GOT WRITTEN (CO)-RAPPORTEURS JOINT ASSESSMENT REPORT STATING CONCLUSION NO FURTHER CONCERNS REMAIN RELATED TO CHS-1701 APPLICATION.  Full Article

Coherus Biosciences Says CHMP Requires Further Interactions With Co Regarding It's Pegfilgrastim Biosimilar
Tuesday, 26 Jun 2018 

June 25 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES SAYS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ISSUED A DRAFT AGENDA AHEAD OF THEIR JUNE 25 TO 28 MEETING - SEC FILING.COHERUS BIOSCIENCES - FURTHER INTERACTIONS WITH CO REGARDING PEGFILGRASTIM BIOSIMILAR PRODUCT CANDIDATE CHS-1701 ISSUES ARE REQUIRED PRIOR TO CHMP OPINION.COHERUS BIOSCIENCES - ANTICIPATES INTERACTIONS WITH CHMP TO OCCUR PRIOR TO NEXT CHMP MEETING ON JULY 23 TO 26.  Full Article

Coherus Prices Public Offering Of Common Stock
Wednesday, 23 May 2018 

May 22 (Reuters) - Coherus BioSciences Inc ::COHERUS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.17 MILLION COMMON SHARES PRICED AT $14.50PER SHARE.  Full Article